ArticleOncotarget2011
Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies.
Article in Oncotarget, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 55 citations in OpenAlex.
- Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population.Frontiers of medicine · 2016Trial
- JAK2 V617F mutations and thrombosis in BCR-ABL1 negative myeloproliferative neoplasms: clinical profile and hematologic insights.Leukemia research reports · 2026Article
- Ruxolitinib reverses systemic vasculitis driven by JAK2 V617F-mutated essential thrombocythemia: a case report.Frontiers in immunology · 2026Article
- Cost-utility analysis of ropeginterferon alfa-2b to manage low-risk patients with polycythemia vera as compared to phlebotomy only in the Austrian healthcare system.Annals of hematology · 2025Article
- Portal vein thrombosis as extraintestinal complications of Crohn's disease: a case report and review of literature.Journal of medical case reports · 2024Review
- Clustering rare diseases within an ontology-enriched knowledge graph.Journal of the American Medical Informatics Association : JAMIA · 2023Article
- Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms.American journal of hematology · 2023Article
- Bilateral adrenal and pulmonary haemorrhages as an initial presentation of polycythaemia vera.BMJ case reports · 2022Article
- Treatment Patterns, Health Care Resource Utilization, and Cost in Patients with Myelofibrosis in the United States.The oncologist · 2022Article
- Genomic Analysis of Hematopoietic Stem Cell at the Single-Cell Level: Optimization of Cell Fixation and Whole Genome Amplification (WGA) Protocol.International journal of molecular sciences · 2020Article
- The effects of mutational profiles on phenotypic presentation of myeloproliferative neoplasm subtypes in Bosnia: 18 year follow-up.Bosnian journal of basic medical sciences · 2020Article
- HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms.Blood · 2020Article
- Janus Kinase V617F Mutation Detection in Patients with Myelofibrosis.Balkan journal of medical genetics : BJMG · 2019Article
- Successful treatment of pulmonary embolism in a patient with polycythemia vera by rheolytic thrombectomy.Journal of cardiovascular and thoracic research · 2019Article
- Article
- Article
- Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment.Frontiers in cell and developmental biology · 2018Review
- Myeloproliferative neoplasms (MPNs) - Part 1: An overview of the diagnosis and treatment of the "classical" MPNs.Canadian oncology nursing journal = Revue canadienne de nursing oncologique · 2018Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most BCR-ABL1-negative myeloproliferative neoplasms (MPN) carry an activating JAK2 mutation. Approximately 96% of patients with polycythemia vera (PV) harbors the V617F mutation in JAK2 exon 14, whereas the minority of JAK2 (V617F)-negative subjects shows several mutations in exon 12. Other mutation events as MPL, TET2, LNK, EZH2 have been described in chronic phase, while NF1, IDH1, IDH2, ASX1, CBL and Ikaros in blast phase of MPN. The specific pathogenic implication of these mutations is under investigation, but they may have a role in refinement of diagnostic criteria and in development of new prognostic models. Several trials with targeted therapy (JAK inhibitors) are ongoing mostly involving patients with PMF, post-PV MF and post-essential thrombocythemia (ET) MF. Treatment with ruxolitinib and TG101348 has shown clinically significant benefits, particularly in improvement of splenomegaly and constitutional symptoms in MF patients. On the other hand, JAK inhibitors have not thus far shown disease-modifying activity therefore any other deduction on these new drugs seems premature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.